Collections
@industrydocs on Twitter
Industry Documents RSS Feed
New Opioid Industry Documents Archive Collection - Teva and Allergan Documents
OIDA staff released the first tranche from its newest collection, the Teva and Allergan Documents. This first batch numbers more than 120,000 documents; the collection will encompass about 1.9 million documents when complete.
Teva Pharmaceuticals, an Israeli company, is one of the United States’ biggest manufacturers of generic opioids, including oxycodone. Teva also manufactures the branded fentanyl products Actiq and Fentora. Ireland-based Allergan formerly made Norco- and Kadian-branded and generic opioids.
Teva acquired Cephalon in 2011 as a wholly-owned subsidiary of Teva Ltd., which added Actiq and Fentora to Teva’s portfolio. In 2016, Teva acquired Allergan’s generics business, Actavis. Allergan/Actavis was the second largest manufacturer to supply generic opioids to the United States, following Mallinckrodt. Allergan was acquired by AbbVie in 2019.
On November 23, 2022, attorneys general in eight states announced that proposed nationwide settlements totaling $6.6 billion had been reached with Teva and Allergan, resolving allegations that they contributed to the opioid crisis by illegally marketing their opioids and failing to maintain effective diversion controls. The nationwide settlements, which became effective in August 2023, call for Teva to pay a total of $4.24 billion over 13 years and Allergan to pay $2.37 billion over seven years.
The settlements prohibit Teva and Allergan from promoting opioids, directly and through front groups, and from engaging in opioid-related lobbying activities. The settlements also require the companies to turn over for public disclosure millions of internal documents they produced in the litigation.
Documents in the collection so far include emails, spreadsheets, presentations, reports, sales training materials, speaker program records, clinical study documentation, depositions and exhibits, trial exhibits, trial transcripts, privilege logs, and other court documents. Processed documents are being made public on a rolling basis with monthly releases expected from 2024-2026.
346,902 new JUUL Labs documents were uploaded today!
This new batch of documents includes customer complaint files, weekly social media reports, international markets retail strategies, and more.
In partnership with the University of North Carolina at Chapel Hill Libraries, the IDL continues to process and make available documents subject to public disclosure under JUUL Labs’s 2021 settlement with North Carolina.
Opioid Crisis Timeline
Through OIDA documents, we can see the opioid crisis unfold. A new research resource, the timeline, introduces important pivot points in the epidemic by guiding readers to primary source documents, relevant scholarship, and contemporaneous journalistic accounts about the crisis.
New Papers and Publications
